The design
UC Davis describes engineered human cytomegalovirus protein-derived variants that engage DR5 and sequester CD155. The design aims to couple a tumor-cell death signal with reduced TIGIT inhibitory engagement. It is a published technology disclosure, not a peer-reviewed clinical result.
The proposed design links receptor clustering to CD155 sequestration. Claims of clinical superiority in the marketing disclosure should be treated as a proposed benefit, not demonstrated patient benefit.
Evidence described publicly
The public disclosure describes engineered variants and mechanistic intent. It does not provide a complete peer-reviewed methods and efficacy record suitable for independent quantitative comparison.
- Dual-action design is disclosedUC Davis states that the variants activate DR5 signaling and sequester CD155 in described experiments.Source (external link)
- An international application is publishedThe disclosure lists PCT publication WO2024/050058, published March 7, 2024.Source (external link)
Record and status
UC Davis technology 33058; clinical benefit is unestablished.
Invention disclosure and published application. Clinical safety, efficacy and licensing status are not established by the public listing.
Read the official patent or technology record (external link)